All In Biotech

Drug Trial Radar · NCT00439374

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Nulliparous Women With a Short Cervix

Last checked: Nov 19, 2026Latest source record: Jul 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 657 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

657

Actual

Start

Apr 2007

Primary completion

May 2011

Study completion Dec 2011

Sponsor

Lead sponsor
The George Washington University Biostatistics CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Feb 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if giving progesterone medication to pregnant women, who have never delivered a baby after 19 weeks of pregnancy and who have a short cervix, lowers the risk of early delivery and improves the health of their baby.

Conditions

  • Preterm Delivery
  • Cervical Length

Interventions

  • 17 alpha-hydroxyprogesterone caproateDrug

    Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.

  • Placebo OilOther

    Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Delivering Before 37 Weeks GestationTime frame: Delivery before 37 weeks gestation

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham

    Birmingham, Alabama

  • Northwestern University-Prentice Hospital

    Chicago, Illinois

  • Dept of OB/GYN, Hutzel Hospital

    Detroit, Michigan

  • Columbia University-St. Luke's Hospital

    New York, New York

  • University of North Carolina - Chapel Hill

    Chapel Hill, North Carolina

  • Case Western Reserve-Metrohealth

    Cleveland, Ohio

  • Ohio State University Hospital

    Columbus, Ohio

  • Oregon Health & Sciences University

    Portland, Oregon

  • University of Pittsburgh-Magee Womens Hospital

    Pittsburgh, Pennsylvania

  • Brown University -Women and Infants Hospital

    Providence, Rhode Island

  • Dept of OB/GYN, Southwestern Medical Center, University of Texas

    Dallas, Texas

  • University of Texas Medical Branch - Galveston

    Galveston, Texas

  • University of Texas-Houston

    Houston, Texas

  • University of Utah Medical Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.